Although FERMT2 is associated with the clinical features of GC patients and has been shown to be an upstream factor promoting GC invasion, the gene was found to have a low correlation with the currently well-known immune checkpoint PD-1. This evidence concerns the gene PDCD1 and gastric cancer.